Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer

Geoffrey R Oxnard

doi:10.5858/arpa.2012-0254-RA

Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer

Arch Pathol Lab Med. 2012 Oct;136(10):1205-9. doi: 10.5858/arpa.2012-0254-RA.

Author

Geoffrey R Oxnard¹

Affiliation

¹ Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, 02215, USA. Geoffrey_Oxnard@DFCI.harvard.edu

PMID: 23020725
DOI: 10.5858/arpa.2012-0254-RA

Abstract

Acquired resistance to targeted therapy in epidermal growth factor receptor (EGFR)-mutant lung cancer represents a valuable model for considering strategies of overcoming different types of cellular resistance mechanisms. Using existing data on resistance in EGFR-mutant lung cancer, this review will discuss 3 basic approaches for overcoming resistance to EGFR-targeted therapies: intensification of EGFR inhibition, combination of EGFR inhibitors with other targeted therapies, and changing to anticancer therapies acting via alternate pathways.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Drug Resistance, Neoplasm*
ErbB Receptors / antagonists & inhibitors*
ErbB Receptors / genetics
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Molecular Targeted Therapy / methods*

Substances

Antineoplastic Agents
ErbB Receptors